Arcellx(US:ACLX)2024-05-09 20:10Financial Position - As of March 31, 2024, Arcellx had cash, cash equivalents, and marketable securities totaling $691.0 million, expected to fund operations into 2027[2] - Total assets as of March 31, 2024, were $779.7 million, down from $825.1 million at the end of 2023[10] - Total liabilities decreased to $283.1 million as of March 31, 2024, compared to $339.8 million at the end of 2023[10] Revenue and Expenses - Collaboration revenue increased to $39.3 million for Q1 2024, up from $17.9 million in Q1 2023, representing a growth of 119%[3] - Research and development expenses decreased slightly to $32.3 million in Q1 2024 from $32.9 million in Q1 2023, a reduction of 1.8%[4] - General and administrative expenses rose to $22.7 million in Q1 2024, an increase of 47.4% compared to $15.4 million in Q1 2023[5] - Net loss for Q1 2024 was $7.2 million, significantly improved from a net loss of $27.3 million in Q1 2023[6] Product Development - The company’s lead product candidate, anito-cel, is in a Phase 2 pivotal trial for relapsed or refractory multiple myeloma[7] - Arcellx is also developing ARC-SparX, a controllable CAR T therapy, through two Phase 1 programs targeting different hematological malignancies[8] Shareholder Information - The weighted-average common shares outstanding increased to 52,757,973 in Q1 2024 from 46,769,380 in Q1 2023[12]